Moderate EULAR Response Research Articles

OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and safety of APR with placebo (PBO)...

FRI0297 Rituximab in Rheumatoid Arthritis – 4 Years Interim Analysis of the Non-Interventional Bridging Study

BackgroundClinical routine data on the efficacy and safety of rituximab (RTX) in patients suffering from severe active rheumatoid arthritis (RA) are assessed in the German BRIDGING study.MethodsBRIDGING is an ongoing...

FRI0302 Tocilizumab, DMARDS and Glucocorticoids in Rheumatoid Arthritis – Interim Analysis of the German Non-Interventional Study Ichiban

BackgroundThe ICHIBAN study collects routine clinical data to evaluate the effectiveness and safety of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) in real world practice over a period of...

FRI0032 Towards MRI Response Criteria for Rheumatoid Arthritis: Does the Course of Magnetic Resonance Imaging Predict Eular Response or Disease Progression?

ObjectivesTo define criteria based on the OMERACT rheumatoid arthritis MRI score (RAMRIS) which correspond to the 1-year EULAR response in a cohort of patients with rheumatoid arthritis.Methods94 patients (62 female...

AB0448 Drug Survival of A Patients Cohort with Chronic Inflammatory RHEUMATISM Treated with Abatacept

ObjectivesThe persistence in therapy is an important assessment tool of therapy efficacy in patient with chronic disease. The aim of this study was to evaluate drug survival (DS) of a...

A1.27 Serum rituximab level and other predictors for good eular response before re-treatment in rheumatoid arthritis

Background and ObjectivesPredictive factors for rituximab (RTX) response in rheumatoid arthritis (RA) patients are currently still under debate. Repeated re-treatment is now the rule, but it is worth knowing if...

SAT0149 High EULAR response rate in rheumatoid arthritis patients switching or dose-escalating anti-TNF therapy

BackgroundIntroduction of infliximab and adalimumab has been a major advance in the treatment of rheumatoid arthritis (RA), but some patients initially responding to infliximab 3 mg/kg/8th week are unable to...

AB0555 Correlations between RF and ACPA dynamics and achievement of response in active rheumatoid arthritis patients treated with rituximab

BackgroundRheumatoid arthritis (RA) is a chronic inflammatory joint disease with a prevalence ranging from 0,5-1% in the general population, associated with premature mortality, disability and compromised quality of life. The...

OP0026 Sustained and cumulated response over time in ra patients treated with rituximab after initial failure of anti-TNF agents

BackgroundAlthough anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency of the initial drug or prescribing...

AB0521 A single-arm, open-label study of the safety and effectiveness of tocilizumab in combination with methotrexate, in patients with rheumatoid arthritis in latin america – preliminary effectiveness results-ritmo study

ObjectivesTo present the preliminary effectiveness data of TCZ + MTX treatment, with regard to reduction in signs and symptoms over 6 months in Latin American pts with mod/severe RA, MTX-IR.MethodsRitmo...

FRI0174 A multibiomarker disease activity score (vectra™ da score) reflects clinical disease activity and tracks response in rheumatoid arthritis patients treated with anti-TNF therapy

BackgroundAnti-TNF therapy has been grown to a standard therapeutic strategy for rheumatoid arthritis (RA). To date, we have developed a multi-biomarker disease activity algorithm (MBDA) as a potential index to...

THU0243 A Comparison of Fenofibrate and Simvastatin Anti-Inflammatory Effects in the Treatment of Rheumatoid Arthritis

BackgroundStatins have been demonstrated to reduce disease activity in rheumatoid arthritis (RA) patients. There is growing evidence that another class of hypolipidemic drugs – PPARalpha agonists, or fibrates, may play...

SAT0294 Monitoring disease activity in early psoriatic arthritis with ultrasound - comparison of clinical responders and nonresponders

BackgroundAssessment of disease activity in early psoriatic arthritis (PsA) is a challenge because of the potential underestimation of the extent of inflammation by clinical examination and the absence of disease-specific...

SAT0280 Efficacy of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis, Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators.ObjectivesPALACE 3 compared APR vs placebo (PBO) in patients with active psoriatic arthritis (PsA) and 1 or more...

SAT0147 Effect of smoking on response to therapy with TNF-A inhibitors for rheumatoid arthritis: Results from the corrona registry

BackgroundTNF-a inhibitors (TNFi) have revolutionized the therapy of Rheumatoid Arthritis (RA). However, up to 30% of patients fail to respond to treatment (tx) with TNFi or respond inadequately. Factors affecting...

AB0569 Effects of tocilizumab in combination with non biologic DMARDS on early improvement of anemia and fatigue in adult patients with moderate to severe active rheumatoid arthritis

BackgroundA significant number of RA patients (pts) have low haemoglobin (Hb) levels. Normalisation of Hb in anaemic RA pts may be a suitable marker of improvement in disease activity, as...

AB0511 Rituximab in rheumatoid arthritis – interim analysis of the non-interventional bridging study

ObjectivesThe BRIDGING study collects clinical routine data on the efficacy and safety of rituximab (RTX) in patients suffering from severe active rheumatoid arthritis (RA).MethodsBRIDGING is a prospective, non-interventional study with...

AB0362 Tight control of disease activity by conventional DMARDs could minimize the use of biological therapies in patients with early rheumatoid arthritis: Data from an early arthritis clinic in hong kong

ObjectivesTo examine the treatment outcome at 1 year of patients treated with tight control of the disease in a prospective cohort of patients with newly diagnosed rheumatoid arthritis (RA).MethodsAll patients...

FRI0219 Disease severity, no steroid use and type ii diabetes predict response to anakinra (kineret®) in patients with rheumatoid arthritis

Background458 patients with rheumatoid arthritis (RA) and unsatisfactory response to DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist anakinra. The initial analysis showed no difference...

AB0303 Tocilizumab in rheumatoid arthritis – annual interim analysis of the german non-interventional study ichiban

BackgroundThe ICHIBAN study collects routine clinical data to evaluate the effectiveness and safety of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) in real world practice over a period of...